Treat Beyond the Clot.
Get Back to What Matters.
Real-time data to guide clinical decisions when treating blood clots in the lungs
Pulmonary embolism (PE)- 3rd leading cause of cardovascular death in US
.png)
Pulmonary embolisms every year in the US
.png)
of PE survivors suffer persistent functional or physical limitations
1 yr post-PE
Clinicians need accessible, advanced therapies that provide precise, real-time data to take the quesswork out of reperfusion and give them confidence that treatment is working and heart function is recovering.
The Versus® Catheter
Hemodynamic-Guided Thrombolysis
Know When Treatment is Working.
Know When Treatment is Done.
Versus is the only FDA-cleared catheter pairing bilateral therapy delivery with integrated real-time pulmonary artery pressure monitoring in a single device for precise, personalized treatment.
Leadership Team
John Schindler
Co-founder, CEO
Derek Hall
Co-founder, COO
Board of Directors
Gabriele Niederaurer, PhD
Board Chair, Advisor
Mary Byron
Board Member, Advisor
Paul Sartori
Board Member, Advisor
2027
-
IDE Clinical Trial Start
-
Expanded PE Indication
-
Limited US Market Release
-
OUS Clinical Cases
2026
-
9Fr FDA Clearance
-
Market Release Preparations
2025
-
9Fr Design Freeze
-
9Fr 510(k) Submission
-
Accelerate Investor Finalist
-
Rice Alliance Award
-
Most Promising LIfe Science Company
-
2024
-
Human Factors Usability Study
-
8Fr 510(k) Submission
-
8Fr FDA Clearance
-
Accelerate Investor Finalist
-
J Lab Residency
-
Lighthouse Lab Accelerator
-
People's Choice Award
-
2023
-
FDA Safety Study
-
BioComp Testing
-
FDA Pre-Sub #3 and #4
-
Catalyst Grant Award
-
VIPC CCF Grant Award
2022
-
Preclinical Studies
-
FDA Pre-Sub #2
-
8Fr Design Freeze
-
MedTech Innovator
-
Vision Award Recipent
-
2021
-
Liquet Medical Incorporated
-
8F Product Development
-
FDA Pre-Sub #1
-
NSF ICorps Participation
-
434 Accelerator Award
Delivering Accessible, Advanced Reperfusion
Our Partners
